Cullinan Oncology, Inc. (now identified in the request as Cullinan Therapeutics, Inc.) — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; filed May 14, 2021. The filing’s registrant name is Cullinan Oncology, Inc. (Nasdaq: CGEM). Amounts below are in U.S. dollars; financial statement amounts are generally in thousands unless noted.
Business context
The company is an early-stage biopharmaceutical developer using a “hub-and-spoke” structure to advance oncology and immuno-oncology programs through partially owned subsidiaries. It had no approved products and no product sales. Its lead clinical candidate was CLN-081; CLN-049 and CLN-619 were preclinical. The quarter included the company’s January 2021 IPO and corporate reorganization, including a one-for-7.039 reverse stock split.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2021 |
|---|---|---|
| License revenue | $0 | $18.9 million |
| Research and development expense | $4.2 million | $12.4 million |
| General and administrative expense | $1.4 million | $5.2 million |
| Total operating expenses | $5.5 million | $17.6 million |
| Consolidated net income (loss) | $(5.2) million | $1.4 million |
| Net income (loss) attributable to Cullinan common stockholders | $(5.0) million | $(0.07) million |
| Net cash used in operating activities | $(5.0) million | $(1.5) million |
Q1 2021 license revenue was the recognized portion of a $20 million upfront payment from Zai Lab for CLN-081 rights in China, Hong Kong, Macau and Taiwan; after foreign tax withholdings, Cullinan recognized $18.9 million. The company recorded $3.0 million of related research and development expense payable to Taiho under its existing arrangements. Consolidated net income included $1.5 million attributable to noncontrolling interests, so Cullinan itself reported a small loss attributable to common stockholders. No income tax provision was recorded. Gross or operating margins are not a meaningful measure of product economics because the company had no product sales; the filing does not report a product margin.
At March 31, 2021, cash and cash equivalents were $293.5 million, short-term investments $147.3 million and long-term investments $32.1 million, or approximately $473.0 million combined. Current assets were $447.3 million and current liabilities $9.9 million. Total liabilities were $10.0 million; the filing reports no borrowings or outstanding debt. Operating cash outflow was $1.5 million. Investing activities used $137.7 million, primarily reflecting purchases of investments, while financing activities provided $264.6 million, primarily from the IPO. Cash and cash equivalents increased by $125.3 million during the quarter.
Material changes versus the prior comparable period
- Revenue increased from zero to $18.9 million, primarily due to the Zai Lab license payment; this was collaboration/license revenue, not product sales.
- R&D expense rose $8.2 million, reflecting increased CLN-081 trial enrollment, CLN-049 IND-enabling and manufacturing work, CLN-619 activity, early-stage research, headcount and equity compensation. Apollo/VK-2019 wind-down partly offset the increase.
- G&A expense rose $3.8 million, driven by equity compensation, increased staffing and public-company costs.
- In January, the IPO issued 13,685,000 shares at $21.00 per share and generated approximately $264.5 million in net proceeds. Shares outstanding at March 31 were 43,516,125.
- Operating cash use declined from $5.0 million to $1.5 million, while the financing and investing cash flows changed substantially due to the IPO and investment purchases.
Outlook, management commentary and risks
- Management expected available cash, cash equivalents and investments to fund operations through 2024, subject to assumptions that could prove incorrect. The financial statement liquidity note separately says resources were sufficient for at least the next 12 months; investors should reconcile the different stated horizons.
- Management expected R&D and public-company costs to increase and anticipated continued operating losses. The company will require substantial funding for development and may need future equity, debt, collaboration or licensing financing, which could dilute shareholders or require granting rights.
- COVID-19 had not caused a reported financial impact, but had affected the pace of clinical-trial enrollment and preclinical studies. Further operational, enrollment, supply or financing effects remained uncertain.
- Key risks include early-stage clinical and regulatory uncertainty, patient recruitment, safety and efficacy, reliance on third-party research and manufacturing providers, intellectual-property protection, competition, and dependence on a limited number of programs and subsidiaries.
- CLN-049’s IND had been submitted in January 2021, then withdrawn following FDA feedback while the company assessed a path forward. Cullinan also planned to dissolve Cullinan Apollo after winding down VK-2019 trial activity.
- There were no material legal proceedings reported. The company said disclosure controls were effective at the reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the recognized Zai Lab revenue, tax withholding, and the associated $3.0 million Taiho expense, including how future milestones and royalties would be recognized.
- Assess the basis and assumptions for management’s “through 2024” cash runway statement against the separate 12-month liquidity statement and planned development spending.
- Track CLN-081 clinical progress and enrollment, and the regulatory and development timelines for CLN-049 and CLN-619, including the status of the withdrawn CLN-049 IND.
- Review subsidiary ownership, noncontrolling interests, investor rights and potential dilution—particularly Cullinan’s 35% fully diluted ownership in MICA and milestone-dependent financing obligations.
- Monitor increasing R&D costs, cash burn, equity compensation, and whether the company needs additional financing before reaching clinical or commercial milestones.